Astragalus polysaccharides improve adjuvant chemotherapy-induced fatigue for patients with early breast cancer

• Published in: Scientific reports 2024-10, Vol.14 (1), p.25690-9, Article 25690
• Main Authors: Shen, Wen-Chi, Chen, Shin-Cheh, Wang, Cheng-Hsu, Hung, Chao-Ming, Peng, Meng-Ting, Liu, Chien-Ting, Chang, Yueh-Shih, Kuo, Wen-Ling, Chou, Hsu-Huan, Yeh, Kun-Yun, Wu, Tsung-Han, Wu, Chun-Feng, Chang, Pei-Hung, Huang, Yen-Min, Yu, Chi-Chang, Lee, Chun-Hui, Rau, Kun-Ming
• Format: Article
• Language: English
• Subjects: 692/4028/67; 692/4028/67/1347; Adjuvant chemotherapy; Adult; Anthracycline; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Astragalus membranaceus; Astragalus Plant - chemistry; Astragalus polysaccharides; Breast cancer; Breast Neoplasms - drug therapy; Cancer-related fatigue; Chemotherapy; Chemotherapy, Adjuvant; Chemotherapy-related fatigue; Fatigue; Fatigue - chemically induced; Fatigue - drug therapy; Female; Global health; Humanities and Social Sciences; Humans; Middle Aged; multidisciplinary; Placebos; Polysaccharides; Polysaccharides - pharmacology; Polysaccharides - therapeutic use; Public health; Quality of Life; Saccharides; Science; Science (multidisciplinary); Sleep disorders; Toxicity
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-76627-z

This study aimed to evaluate the effect of Astragalus polysaccharides (PG2) on reducing chemotherapy-induced fatigue (CIF) and toxicity, thereby encouraging compliance to chemotherapy. This was a randomized, placebo-controlled, phase 2 study. Patients with stage II/III early breast cancer planning to undergo adjuvant anthracycline-based chemotherapy were randomly assigned to receive PG2 500 mg or placebo on days 1, 3, and 8 every 21 days. The fatigue global score (FGS) was assessed using the brief fatigue inventory (BFI)-Taiwan. The Breast Cancer-Specific Module of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Core30 evaluated the health-related quality of life during the first four cycles of adjuvant chemotherapy. Overall, 66 eligible patients were equally randomized into the PG2 and placebo groups between March 01, 2018, and March 09, 2021. The mean change in the FGS and fatigue intensity did not significantly differ between both groups. However, the FGS and fatigue intensity were less aggravated in the first four cycles in the premenopausal-PG2 group than in the placebo group. Our study concluded PG2 combined with adjuvant chemotherapy can reduce CIF, insomnia, the negative effect on future perspectives, and improve global health status, especially for premenopausal patients with breast cancer. Trial registration number: NCT03314805 registered on 19/10/2017.